A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women
Status:
COMPLETED
Trial end date:
2025-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of cytochrome P450 isoenzyme 2D6 (CYP2D6) inhibition by quinidine on the pharmacokinetic (PK) parameters of a single dose SEP-380135 in healthy adult participants.
Phase:
PHASE1
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.